| First Author | Emerling BM | Year | 2013 |
| Journal | Cell | Volume | 155 |
| Issue | 4 | Pages | 844-57 |
| PubMed ID | 24209622 | Mgi Jnum | J:205288 |
| Mgi Id | MGI:5544525 | Doi | 10.1016/j.cell.2013.09.057 |
| Citation | Emerling BM, et al. (2013) Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell 155(4):844-57 |
| abstractText | Here, we show that a subset of breast cancers express high levels of the type 2 phosphatidylinositol-5-phosphate 4-kinases alpha and/or beta (PI5P4Kalpha and beta) and provide evidence that these kinases are essential for growth in the absence of p53. Knocking down PI5P4Kalpha and beta in a breast cancer cell line bearing an amplification of the gene encoding PI5P4K beta and deficient for p53 impaired growth on plastic and in xenografts. This growth phenotype was accompanied by enhanced levels of reactive oxygen species (ROS) leading to senescence. Mice with homozygous deletion of both TP53 and PIP4K2B were not viable, indicating a synthetic lethality for loss of these two genes. Importantly however, PIP4K2A(-/-), PIP4K2B(+/-), and TP53(-/-) mice were viable and had a dramatic reduction in tumor formation compared to TP53(-/-) littermates. These results indicate that inhibitors of PI5P4Ks could be effective in preventing or treating cancers with mutations in TP53. |
